Association of the CB1 receptor antagonist and sibutramin, for treating obesity

Details for Australian Patent Application No. 2001293936 (hide)

Owner Aventis Pharma S.A.

Inventors Petitet, Francois; Piot-Grosjean, Odile; Picaut, Philippe

Agent Watermark

Pub. Number AU-B-2001293936

PCT Pub. Number WO02/28346

Priority 00 /12646 04.10.00 FR

Filing date 1 October 2001

Wipo publication date 15 April 2002

Acceptance publication date 25 January 2007

International Classifications

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 31/135 (2006.01) - having aromatic rings, e.g. methadone

A61K 31/137 (2006.01) - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

25 January 2007 Application Accepted

  Published as AU-B-2001293936

24 May 2007 Standard Patent Sealed

28 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001293937

2001293935